Emergent BioSolutions (EBS) Change in Receivables (2010 - 2026)

Emergent BioSolutions' Change in Receivables history runs 17 years deep, the most recent figure standing at $38.9 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 46.93% year-over-year to $38.9 million; the TTM figure through Mar 2026 stood at -$59.9 million (down 225.58% YoY), while the FY2025 annual figure was -$25.5 million, down 204.51% from the prior year.
• Change in Receivables was $38.9 million for Q1 2026 at Emergent BioSolutions, up from -$51.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $132.4 million in Q2 2023 to a low of -$118.5 million in Q2 2025.
• Historically, Change in Receivables has averaged -$3.5 million across 5 years, with a median of -$4.0 million in 2022.
• Biggest YoY gain for Change in Receivables was 3410.0% in 2023; the steepest drop was 569.08% in 2023.
• A 5-year view of Change in Receivables shows it stood at -$35.6 million in 2022, then fell by 3.65% to -$36.9 million in 2023, then soared by 308.94% to $77.1 million in 2024, then slumped by 167.32% to -$51.9 million in 2025, then soared by 174.95% to $38.9 million in 2026.
• The last three Change in Receivables figures came in at $38.9 million (Q1 2026), -$51.9 million (Q4 2025), and $71.6 million (Q3 2025), per Business Quant data.